Chimera Peptides
chimera-peptides.com
Email me when this record changes
Following this record emails you when it gains a dated entry or its published claims are re-read, and nothing about any other supplier. No topic below is ticked: tick one only if you also want it in the same email.
Compiled automatically from the dated observations in this vendor's record. How we evaluate.
Never merged into one number. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Two of Chimera Peptides' own published retatrutide certificates, both issued under the BTLabs/Finnrick brand, report potency outside the acceptance range printed on the same document: the 40mg certificate, Lot NP24BXJ, reads 107.5 percent of label against a stated 95 to 105 percent band, and the 60mg Test 2 certificate, Lot RNEZA7F, reads 110.6 percent against the same band, both by HPLC potency assay under USP 621. The Customer field on those Finnrick-brand documents names Finnrick itself rather than Chimera Peptides, the expected signature of a test the storefront did not order, which reads in the documents' favour, while the storefront's own 30mg 'Test 1' and 30mg 'Test 2' buttons, presented as separate certificates, open different image files that turn out to be the identical Janoshik document, task #90420, verification key R6RFG41WFWH9, whose own batch field reads Unknown. A reader who has received a recent retatrutide batch could say whether its lot number matches any of these documents, given that some carry a specific batch and others record it as Unknown.
What the record holds
NO FIRM COMMITMENT
“Processing times may vary depending on order volume, weekends, holidays, and product availability... Delivery times are estimates and are not guaranteed”
no business-day count, no rate, and no carrier named on the shipping page; refund policy is fully discretionary with no committed timeframe even for a carrier-confirmed loss
Read from this supplier's own pages on 2026-08-25. This publication has never placed an order with any supplier. This row records what is written and measures nothing about what actually happens after an order.
$155.0010mg × 10 vials price
Compound retatrutide 10mg x 10 vials (ten-vial kit; no single 10mg vial sold)
Listed as Retatrutide, a single product page with a Select Specification dropdown; the 10mg option is sold as "10mg x 10vials," a ten-vial kit, not a single 10mg vial
Price as recorded $155.00 for the 10mg x 10vials kit, read from /product/retatrutide/. Across the dropdown: $114.00 (5mg), $155.00 (10mg), $162.00 (15mg), $169.00 (20mg), $228.00 (30mg), $265.00 (40mg), $312.00 (50mg), $359.00 (60mg), each figure the price of a ten-vial kit at that per-vial strength
Read on 2026-08-25. One reading on one day, and prices are not tracked over time here.
This supplier was not part of the Trustpilot reading of 2026-08-25, which covered 59 of the 126 suppliers on file. That is a fact about this publication's coverage, stated rather than left to be read either way.
7 claims from this publication's own dossier on this supplier were read again against the live site on 2026-08-25: 0 held, 7 corrected before publication.
A corrected claim is an error of ours that the re-read caught before it reached a page. This line tracks this publication's own accuracy. It says nothing about the supplier.
Dated entries
4 observations on file, recorded 2026-08-25. Newest first, appended and never rewritten.
The /coas/ page is a client-rendered picker: choose a product and a dose, and the page opens a modal image rather than listing files directly. Reading the button markup rather than the rendered page, it offers twelve documents: Retatrutide at 10mg, 15mg, 20mg, 30mg (Test 1), 30mg (Test 2), 40mg, 60mg (Test 1) and 60mg (Test 2), Tirzepatide 30mg and a second Tirzepatide 30mg marked (Finnrick), NAD+ 500mg, and a CJC No Dac and Ipamorelin blend. Against a 59-product catalog read from /shop/ today, that is four compounds covered. None of the twelve images is hosted on chimera-peptides.com itself; every data-img attribute points to a second domain, chimera.is, for example https://chimera.is/coa-images/retatrutide-10mg.png. I downloaded and read all twelve. Three laboratories appear across the set, with no explanation anywhere on chimera-peptides.com of why a given dose comes from one rather than another: the retatrutide 10mg, 15mg, 40mg and 60mg (Test 2) documents are BTLabs (Powered by BioTools) certificates issued under the Finnrick Testing Certificate brand, the Tirzepatide (Finnrick) document is issued by Krause Analytical of Austin, Texas under the same Finnrick brand, and the retatrutide 20mg, 30mg (both Test 1 and Test 2) and 60mg (Test 1) documents, plus the default Tirzepatide, NAD+ and CJC-blend documents, are one-page Janoshik Test Report forms. Finnrick is the certificate-issuing and verification brand wrapping the BTLabs and Krause reports, not a laboratory itself. Every multi-page certificate in the set is published as its first page only: the four BTLabs certificates are headed page 1 of 2 and the Krause certificate page 1 of 3, at pixel sizes around 652 by 843 against 1301 by 1920 for the complete one-page Janoshik forms, and the withheld later pages are where chromatograms and spectra would sit. Two of the twelve documents carry no purity value at all, the NAD+ form reporting only a mass of 523.89 mg and the blend form only 5.95 mg and 5.28 mg for its two components, so purity coverage is ten documents across three compounds. The retatrutide 30mg (Test 1) and 30mg (Test 2) buttons open different image files, but the documents behind them are the same test: both carry Janoshik task number 90420, both show Retatrutide 32.89 mg and Purity 99.810%, and both carry the identical verification key R6RFG41WFWH9. A dosage advertised on the page as having two independent tests has one.
Three laboratories stand behind the certificate set and none is named anywhere in the site's own body text; I searched the home, about-us, why-choose-chimera-peptides and retatrutide pages for BTLabs, Janoshik, Krause, Finnrick and BioTools, and only "Finnrick" appears, once, inside the /coas/ button label "Tirzepatide 30mg COA (Finnrick)." On the Finnrick-brand documents the Customer field reads "Finnrick," not Chimera Peptides, which is the expected signature of a test the storefront did not order: Finnrick's own vendor page states samples may be acquired by Finnrick directly or submitted through its testing programs, so a customer field naming the testing party reads as provenance in the documents' favour. The retatrutide 10mg certificate is Report IF-824-QSA-TR006-2025-152-16, Lot N38Y4AS, dated 12/29/2025, HPLC Purity of Peptide Assay 99.6 percent against a specification of 98 percent or higher, HPLC Potency Assay 10.3 mg against a 10mg label (103.3 percent of label), and the FTIR Identification and Composition line states the spectrum "confirms the presence of peptide with addition of excipient(s)/fillers such as mannitol," a lyophilisation bulking agent disclosed quantitatively on the same page. It is signed by Kimberly Quinn, MS, Lab Manager, and a second scientist, both of BTLabs, with the lab's address given as 5730 Corporate Way, Suite 220, West Palm Beach, FL 33407, phone (561) 625-0133, and a Finnrick verification instruction reading "Verify at https://finnrick.com/verify." The repeating diagonal watermark across every Finnrick-brand document reads FINNRICK, the testing party's name; the vendor's own mark appears once, as a centered logo graphic beside the vial photograph, not as a watermark. The Tirzepatide (Finnrick) document comes from a third laboratory: Krause Analytical LLC, 8127 Mesa Drive Suite B-206, Austin TX 78759, signed by Mark C. Krause as Laboratory Director, Project 145031, Lab number 200732, sample received 1/29/2026, report issued 2/18/2026, reporting chromatographic purity of 99.63 percent by HPLC-UV/MS and tirzepatide at 32.7 mg, 108.9 percent of a 30 mg label claim; krauselabs.com resolves today to that laboratory at the identical street address. btlabtesting.com resolves today to a live contract-testing laboratory site under the name BTLabs; neither it nor krauselabs.com publishes an ISO 17025, A2LA or other accreditation claim on the pages I loaded. finnrick.com resolves today to Finnrick Analytics LLC, whose homepage title on 2026-08-25 gives 9,879 published lab tests and whose vendor index lists 1,774 vendors, and it maintains a live public page for this storefront at /products/retatrutide/vendors/chimera-peptides showing 14 retatrutide tests, a rating of 91 percent, rank #5 of 252 retatrutide vendors, a dated trend running 13 Oct 2025 through 24 Aug 2026 with the latest test on 5 Aug 2026, and all five certificate IDs printed on the storefront's Finnrick-brand documents, n38y4as, gr4uutt, np24bxj, rneza7f and 5aeknje, listed on that page, so the existence and dating of those five documents are independently corroborated. Finnrick's own analysis line for this vendor puts purity by HPLC across its test set in the 99.6 to 99.9 percent range and names batch documentation as the caveat, noting most tests lack batch IDs and one vial ran 24 percent over label. The per-test purity, dosage and laboratory columns on that page sit behind a paid membership gate at $9.99 per month which this publication did not cross, so the measured values on the published documents are matched to Finnrick's listing but not re-read from it. Within the Finnrick-brand group the dates are 12/05/2025 for the 60mg document, Lot RNEZA7F, 12/29/2025 for the 10mg and the 15mg, Lot GR4UUTT, 1/22/2026 tested and 1/23/2026 dated for the 40mg, Lot NP24BXJ, and the Krause report received 1/29/2026, which is at least three separate submissions across two laboratories. On the Janoshik-format documents, the Client field reads "The Gray Market," not Chimera Peptides, with Manufacturer given as "Chimera" and Batch as "Unknown" on every one I opened; task numbers run 90418 through 90432, testing ordered 19 NOV '25, sample received 25 NOV '25, analysis conducted 26 and 27 NOV 2025, so the Janoshik block, and that block alone, is a single submission roughly nine months old measured against today. janoshik.com is live: a request from this session completed its TLS handshake and received an HTTP 403 bot-protection interstitial titled "Just a moment...", so the laboratory's site is up and refusing automated clients, and the earlier read's handshake failure reproduces only on this machine's schannel-backed curl, a local client limitation rather than a fault at the lab. The eight printed Janoshik verification keys remain unconfirmed either way, because checking them requires passing a bot-protection gate this publication does not attempt.
Catalog, prices and policies read on 2026-08-25. The shop lists 59 products at /shop/. Retatrutide's own page states an age line rather than gating entry behind one: "Age Requirement: You must be 18 years or older to place an order," printed as body text with no checkbox or modal in the markup I fetched, alongside "Research use only; not for human or veterinary use." Payment runs through a single manual rail: the store's own commerce API at /wp-json/wc/store/v1/cart, read today, reports exactly one enabled gateway identifier, bacs, WooCommerce's manual direct bank transfer method, with no card rail and no crypto payment processor installed on the store at all. The sitewide banner reads "Pay with Crypto, 20 percent OFF! Coupon: crypto20," and the dedicated /how-to-pay-with-crypto/ page walks a visitor through buying Bitcoin on Cash App, Changelly or Bitcoin.com and sending it to a supplied wallet address, so the crypto flow is a manual off-store instruction wrapped around a bank-transfer gateway, with payment confirmation depending on an operator reading a message and no chargeback path. Shipping, at /shipping-policy/, commits to no figure at all: "Processing times may vary depending on order volume, weekends, holidays, and product availability... Delivery times are estimates and are not guaranteed," with no business-day count, no rate and no carrier named. The refund policy at /refund_returns/ is fully discretionary: "Submitting a request does not automatically guarantee a refund, replacement, store credit or reshipment. Every case is reviewed individually," with no committed timeframe even for a carrier-confirmed loss. Contact channels are a working web form on /contact-us/, a Contact Form 7 form with name and email inputs that the page's own copy offers first, plus a US mobile number for text or WhatsApp only, +1(804)-280-4884, explicitly "(messages only)"; I found no published email address and no street address on the home, about-us or contact-us pages. The site's schema.org markup gives the organization's legalName as "admin" on every page I fetched, commerce pages included, while the author node naming "admin" appears on the content pages but not on /shop/ or the retatrutide product page, and the site logo file is named cropped-ChatGPT-Image-Aug-22-2026-10_00_56-AM.png in its own upload path. A related domain, chimera.is, hosts the certificate images described above; its own homepage, fetched today, titles itself "Chimera - Research-Grade GLP-1 and Retatrutide Peptides" and carries the Twitter handle @chimerapeptides, matching the Chimera Peptides brand. Its homepage serves a 1,974 byte client-rendered shell, but its single module bundle at /assets/index-DoyIsYut.js, about 670 KB fetched today, is readable and shows a full second storefront under the same brand rather than an image host: cart and checkout code, separate US and overseas warehouse routing, an affiliate dashboard, a supplier portal, a Discord invite at discord.gg/ZpYfTZUW4f and a Supabase backend at esagxmkgwhvzpnippzdg.supabase.co.
CAUTIONCautions noted. First and foremost, half the retatrutide certificates the storefront presents in support of the doses it sells report a potency value outside the acceptance range printed on the certificate's own row: the 40mg certificate reports 43 mg, 107.5 percent of label, by HPLC potency assay under USP 621 against a printed specification of 95 to 105 percent of 40 mg, and the 60mg (Test 2) certificate reports 66.4 mg, 110.6 percent, by the same method against the same band; Finnrick's own summary line for this vendor independently notes one vial ran 24 percent over. Second, a sibling-domain structure that is more than certificate hosting: the operator runs at least three brand domains. chimera.is, carrying the same brand name and Twitter handle, is a second operating storefront with its own cart, warehouse routing, affiliate programme and supplier portal. chimerapeptides.com, unhyphenated, was registered 2025-10-08 per Verisign RDAP, sits on client hold with transfers prohibited, last changed 2026-04-27, and does not resolve; the storefront under review was itself registered 2026-04-05, about four and a half months before this read, so every certificate it publishes predates the storefront's own domain. Any future record on chimera.is or chimerapeptides.com should be checked for duplication or merge against this one before being treated as independent. Third, lot traceability fails end to end: the Janoshik-format documents record the batch as Unknown on every form, Finnrick's own analysis names missing batch identifiers as the caveat on this vendor, and the retatrutide product page's single documentation instruction, to compare the product and lot identifier against the COA library, cannot be carried out against documents with no batch recorded. The customer fields naming Finnrick and The Gray Market rather than the storefront are the expected signature of tests the storefront did not commission, which reads in the documents' favour rather than against them. Fourth, the 30mg (Test 1) and 30mg (Test 2) buttons are presented as two tests and open two different image files, but the documents are the same Janoshik task, the same verification key and the same measured values, so the appearance of duplicate testing is not backed by duplicate testing. Fifth, the published set spans 12/05/2025 to a report issued 2/18/2026, the newest published document about six months old at this read, and only the first page of every multi-page certificate is published, withholding the chromatograms and spectra a reader would need to check the summary values, while each certificate's own testing-purpose line states it does not cover particulate matter, microbial contamination or endotoxins. Sixth, the operator identity on file, in the site's own structured data, is the placeholder word "admin" rather than any legal name, on a storefront whose direct contact channels are a web form and a message-only mobile number with no listed email or street address. Seventh, the site's navigation groups its 59-product catalog under six product categories, four of them outcome-style names rather than compound classes, a body-composition and metabolic-outcome category, a tissue-repair-and-performance-outcome category, a cognitive-outcome category and a sexual-health category, each described here rather than reprinted, plus a general-health category and a catch-all named Others.
Reader reviews
No reader review of this supplier is published yet. Every review is read and checked against the record before it appears. Add a review.
Open this supplier
Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.